The authors would like to draw the reader's attention to errors in the following article:
Tanaka et al. Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma. Cancer Sci 2012; 103: 455–63.
An incorrect dose unit of NBD peptide was printed in the following pages.
On page 457, in the Results section, sub-section Selective inhibition of NF-κB activation using NBD peptide suppresses metastatic potential of highly metastatic OSCC cells in vivo, the correct sentences should read:
We first compared the antimetastatic effects using different concentrations (2, 8, or 16 mg/kg of body weight/day, on day 3, 6, 9, 12, and 15) of the NBD peptide after orthotopic inoculation of the GSAS/N5 cells. The NBD peptide given at 16 mg/kg of body weight/day showed the most potent antimetastatic effect (data not shown).
On page 461, in the legend of Fig 5, the correct sentence should read:
GSAS/N5 inoculated mice were treated with 16 mg/kg of body weight/day NBD peptide or control peptide by i.p. injection on days 3, 6, 9, 12, and 15.
In Supporting Information Data S1, page 3, in the In vivo experimental protocol section, the correct sentence should read:
In the in vivo NF-κB blockade experiment, a group of 20 mice engrafted with GSAS/N5 cells on day 0 were treated with 16 mg/kg of body weight/day of the NBD peptide or the control peptide via i.p. injection on days 3, 6, 9, 12, 15.
The authors apologize for these errors and any confusion it may have caused.